DigestRedComo funciona
Red
/
Empresas
Ar
No verificado

Arrowhead Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCardiologíaFarmacéuticaMedicina - VariosSalud

84 Comunicados de prensa

Ver todos los comunicados de prensa
18/06/2026
Web y redes sociales
Ciencia
Biotecnología
Salud
Medicina - Varios
Cardiología
Sanidad
Farmacéutica
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/06/2026
Eventos
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
27/05/2026
Ciencia
Salud
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Eventos
Industria
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
26/05/2026
Web y redes sociales
Eventos
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
07/05/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/05/2026
Industria
Cardiología
Biotecnología
Sanidad
Salud
Farmacéutica
Ciencia
Medicina - Varios
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/05/2026
Eventos
Cardiología
Salud
Sanidad
Comunicación
Farmacéutica
Ciencia
Biotecnología
Medicina - Varios
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
01/05/2026
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
24/04/2026
Industria
Ciencia
Medicina - Varios
Cardiología
Sanidad
Salud
Farmacéutica
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0